MAHWAH, N.J., March 10, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); ...

Polyethylene Glycol 3350 is indicated for the treatment of occasional constipation. For more information, including Uses, Warnings and Directions, please refer to the product's Drug Facts. ANI ...

Ani Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 Powder for Oral Solution. Ani ...

A meta-analysis shows that polyethylene glycol is more effective than placebo in treating constipation in children and may be ...

Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative that will compete directly with Bayer’s MiraLAX. The ...

According to Nielsen® syndicated data for the latest 52 weeks' period ending February 22, 2025, the MiraLAX® Powder for Solution, 17 grams (OTC) market 3 achieved annual sales of approximately $555.7 ...

Glenmark Therapeutics Inc., USA (Glenmark) announced the launch of polyethylene glycol 3350, powder for solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX powder for solution ...